Cheryl Maley, B.Sc, DipEd, MBA, GAICD
Chief Executive Officer and Managing Director (appointed 8 January 2024)

Cheryl has over 25 years of experience in the pharmaceutical industry, including 20 years in leadership roles at well-known and leading organisations, including Novartis and AbbVie. Her roles include nine years at Novartis in senior commercial and executive roles and various sales and marketing positions with AbbVie/Abbott, Servier Laboratories, and Wyeth Pharmaceuticals.

Cheryl has had extensive experience in leading pharmaceutical innovation, marketing, commercialisation and delivering business growth across Australia, Asia, and international markets. She has a strong commercial background with a proven record in successful product launches and patient access and reimbursement to innovative medicines.

During her nine-year career at Novartis, Cheryl held a number of senior leadership positions where she had responsibility for new products, commercialisation and strategy, as well as reimbursement matters. Cheryl was Country Head and President of Novartis Philippines, where she was responsible for the Pharmaceutical Division and oversaw the cross-divisional leadership team, including the Oncology, Sandoz and Alcon business units.

In her most recent Novartis role as General Manager, Oncology, Australia and New Zealand (ANZ), Cheryl led Novartis’ oncology division in the ANZ region, with P&L responsibility and oversight of all business functions, including medical, commercial/sales, finance, operations, legal, market access, and compliance. In this role, Cheryl oversaw the successful launch of Australia’s first CAR T cell therapy, Kymriah^®, for the treatment of B-cell acute lymphoblastic leukemia, one of Novartis’ top 20 medicines by sales in 2022.

Cheryl has most recently been serving as the Acting CEO and Strategic Advisor at Biointelect, a firm that specialises in strategic planning and commercialisation for the biopharmaceutical and medical device sector. During this time, she has supported a number of research institutions and biotech companies to achieve their goals of growth, transformation and successful commercialisation.

Tony Eglezos, B.Sc (Hons), PhD, MBA
Vice President, Business Development 

Dr Eglezos has worked for more than 20 years in the pharmaceutical industry in Australia, the US and Europe for companies including CSL, Amgen, Abbott Labs and Abbott Australasia. Most recently he was Director Commercial Operations, Pharmaceuticals, and In-Licensing at bioCSL and, prior to that, Senior Director Business Development and Licensing at CSL. During his 7 years in business development with CSL, Tony’s responsibilities included acquisitions and due-diligence, commercialisation of in-licensed pharmaceutical products and out-licensing of IP for partnered development for the global R&D group. Tony has a PhD in Immunology from the University of Melbourne and an MBA from the University of Technology Sydney.

Jeremy Paull, B.Sc (Hons), PhD
Vice President, Development and Regulatory Affairs

Dr Jeremy Paull has more than 20 years’ experience in pharmaceutical and medtech product development, regulatory affairs, and commercialisation.  Jeremy has managed all aspects of multiple development and commercialisation projects for products in areas including HIV/STIs, COVID-19, women’s health, dermatology, and oncology, and has achieved market approval and commercialisation of medical device and combination products in global markets. Jeremy has also advanced pharmaceutical products through late stage, global phase 3 clinical trials, and led engagement with global regulatory agencies (FDA, EMA, TGA, MHRA, PMDA). Jeremy leads a team of senior technical managers and was Principal Investigator for two concurrent US NIH-funded, multi-year, multimillion-dollar research and product commercialisation programs involving collaborations with world-renowned, local and international academic institutions and commercial partners. He is a current member of AusBiotech’s AusMedtech Regulatory Affairs Expert Panel and past member of the AusMedtech Victoria Committee. Jeremy has been a member of the Starpharma’s Management since 2003 and has completed executive leadership training at Kellogg School of Management at Northwestern University, Melbourne Business School, and Australian Graduate School of Management at UNSW. He joined Starpharma in 2001 from medtech company, Norwood Abbey and has a PhD in pharmacology from Monash University.

Justin Cahill, BBus, MPA, CPA
Chief Financial Officer & Company Secretary

Mr Justin Cahill has more than 15 years’ experience in corporate finance and leadership roles in the biopharmaceutical, food, and agricultural sectors for both ASX-listed companies and in private companies. Prior to joining Starpharma, Mr Cahill was Chief Financial Officer (CFO) of Paradigm Biopharmaceuticals; and CFO at Diver Foods; and has held senior roles at ASX-listed company Costa Group and at CSL, including 5 years as Divisional CFO of CSL Plasma based in the United States. In these roles, Mr Cahill was responsible for financial performance, financial planning and reporting, compliance, and capital control. Mr Cahill is a Certified Practicing Accountant (CPA) and holds a Master of Professional Accounting and a Bachelor of Business from Swinburne University.